Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 22, 2020

SELL
$12.82 - $16.85 $68,420 - $89,928
-5,337 Closed
0 $0
Q3 2019

Oct 22, 2019

BUY
$16.31 - $28.29 $22,621 - $39,238
1,387 Added 35.11%
5,337 $92,000
Q2 2019

Jul 23, 2019

BUY
$19.18 - $27.88 $75,761 - $110,126
3,950 New
3,950 $108,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $215M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Convergence Investment Partners, LLC Portfolio

Follow Convergence Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.